The association of the rs1049353 polymorphism of the CNR1 gene with hypoadiponectinemia.
暂无分享,去创建一个
[1] D. D. de Luis,et al. G1359A polymorphism of the cannabinoid receptor gene (CNR1) and insulin resistance in patients with diabetes mellitus type 2. , 2010, Nutricion hospitalaria.
[2] T. Noda,et al. Rimonabant Ameliorates Insulin Resistance via both Adiponectin-dependent and Adiponectin-independent Pathways* , 2009, Journal of Biological Chemistry.
[3] M. Moța,et al. The implication of CNR1 gene's polymorphisms in the modulation of endocannabinoid system effects. , 2009, Romanian journal of internal medicine = Revue roumaine de medecine interne.
[4] F. Salvi,et al. Renin–angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans , 2008, Journal of hypertension.
[5] K. Mackie,et al. Endocannabinoid system and its implications for obesity and cardiometabolic risk , 2008 .
[6] W. Hul,et al. The G1422A variant of the cannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men , 2007, Endocrine.
[7] M. Notarnicola,et al. Association between cannabinoid type-1 receptor polymorphism and body mass index in a southern Italian population , 2007, International Journal of Obesity.
[8] T. Meitinger,et al. No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents. , 2007, Molecular genetics and metabolism.
[9] D. Cota,et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. , 2006, Endocrine reviews.
[10] M. Gonthier,et al. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes , 2006, Histochemistry and Cell Biology.
[11] S. Woods,et al. The role of the endocannabinoid system in the regulation of energy homeostasis , 2005 .
[12] V. Vellani,et al. Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels , 2005, The EMBO journal.
[13] P. Soubrié,et al. The CB1 receptor antagonist rimonabant reverses the diet‐induced obesity phenotype through the regulation of lipolysis and energy balance , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[14] D. Osei-Hyiaman,et al. Evidence for novel cannabinoid receptors. , 2005, Pharmacology & therapeutics.
[15] J. Després,et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. , 2005, The Journal of clinical endocrinology and metabolism.
[16] G. Kunos,et al. Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1. , 2004, European journal of pharmacology.
[17] P. Soubrié,et al. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity , 2004, International Journal of Obesity.
[18] C. Flachskamm,et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. , 2003, The Journal of clinical investigation.
[19] P. Soubrié,et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. , 2003, Molecular pharmacology.
[20] B. Lutz. Molecular biology of cannabinoid receptors. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.
[21] M. Lazdunski,et al. The endocannabinoid anandamide is a direct and selective blocker of the background K+ channel TASK‐1 , 2001, The EMBO journal.
[22] P. Sasieni. From genotypes to genes: doubling the sample size. , 1997, Biometrics.
[23] M. Herkenham,et al. Cannabinoid receptor localization in brain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.